Kalvista Pharmaceuticals Inc expected to post a loss of 91 cents a share - Earnings Preview

Kalvista Pharmaceuticals

03/12/2024 13:33

* Kalvista Pharmaceuticals Inc  KALV.OQ   KALV.O  is
expected
to show no change in quarterly revenue when it reports 
results on December 5 (estimated) for the period ending October
31 2024
    * 
    * ​LSEG's mean analyst estimate for Kalvista Pharmaceuticals
Inc
is for a loss of 91 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Kalvista
Pharmaceuticals Inc is $31.50​, above​ its last closing price
of $10.27. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jul. 31 2024  -0.92       -0.91      -0.87     Beat    4.8
 Apr. 30 2024  -0.84       -0.73      -1.02     Missed  -39.4
 Jan. 31 2024  -0.77       -0.77      -0.84     Missed  -9.5​
 Oct. 31 2023  -0.77       -0.79      -0.80     Missed  -1.7
 ​​Jul.        -0.84       -0.86      -0.74     Beat    13.8
 31 2023                                                
 Apr. 30 2023  -0.83       -0.94      -0.77     Beat    17.9​
 Jan. 31 2023  -0.92       -0.98      -0.75     Beat    23.9
 Oct. 31 2022  -1.03       -1.06      -0.90     Beat    14.8
 This summary was machine generated December 3 at 13:32 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)